Fineline Cube

Follow:
14486 Articles
China Medical System Partners with MabGeek for Innovative Drug MG-K10
CompanyDigital

China Medical System Partners with MabGeek for Innovative Drug MG-K10

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062
CompanyDrug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline
CompanyDeals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA
CompanyDrug

Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
CompanyDeals

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology

Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter
CompanyMedical Device

Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
CompanyDrug

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus

Accuray's Tomo C System Completes Treatment of First 100 Patients in China
CompanyMedical Device

Accuray’s Tomo C System Completes Treatment of First 100 Patients in China

Ascentage Pharma Prices US IPO at USD 17.25 per ADS
CompanyDeals

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

United Laboratories' Biosimilar Semaglutide Accepted for Review by China's NMPA
CompanyDrug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Beijing Aosaikang's ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer
CompanyDrug

Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer

Biogen's Higher-Dose Spinraza Regimen Under Review by FDA and EMA
CompanyDrug

Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA